Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Trial Profile

Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 21 Jun 2018 Results of post-hoc analysis of data from this trial will be presented at the European Network for the Cure of ALS (ENCALS) Annual Meeting (2018).
    • 18 Apr 2018 Results of post-hoc analysis of data from this trial will be presented at the American Academy of Neurology (AAN) 2018, according to a Mitsubishi Tanabe Pharma America media release.
    • 09 Apr 2018 According to a MT Pharma America media release, Health Canada has accepted MTPC's New Drug Submission (NDS) for edaravone, an intravenous treatment option for amyotrophic lateral sclerosis (ALS)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top